To explore the antibacterial spectrum of ozenoxacin and compare its in vitro activity with that of other antibacterial agents. Materials & methods: In 2010, 10,054 isolates were collected from 128 centers worldwide. Minimum inhibitory concentrations against Gram-positive and Gram-negative isolates were determined for 23 and 13 antibacterial agents, respectively. Results: Ozenoxacin exhibited high in vitro activity against susceptible, and methicillin-or levofloxacin-resistant, Gram-positive bacteria. Ozenoxacin was one or two dilutions less active against Enterobacteriaceae isolates, except for Escherichia coli, than other quinolones. Conclusion: Ozenoxacin is a potent antimicrobial agent mainly against susceptible and resistant strains of Gram-positive isolates (staphylococci and streptococci), and shows activity against some Gram-negative isolates.
Impetigo is a common bacterial skin infection affecting children and adults that is caused by Staphylococcus aureus or Streptococcus pyogenes. It is the most common bacterial skin infection in children aged 2-5 years [1, 2] .
Impetigo is commonly treated with topically applied antibacterial agents such as mupirocin, fusidic acid and retapamulin [1] [2] [3] [4] [5] . A recent evidence-based review supported the clinical efficacy of mupirocin and fusidic acid for treatment of impetigo [5] . However, in some cases, development of resistant isolates limits the uses of these agents [1, 5] .
An alternative option for treating impetigo in children and adults is a 1% topical cream formulation of ozenoxacin, a nonfluorinated quinolone with bactericidal activity [6] , which was recently approved in several countries worldwide [7] [8] [9] [10] . Approval of ozenoxacin was granted based on demonstrable clinical benefit in two large Phase III trials of impetigo involving adults and children from 2 months of age [11, 12] . Rapid eradication of bacterial load is important in impetigo to hasten symptom resolution and limit person-to-person transmission of infection.
Early in vitro characterization of ozenoxacin found that it was 3-to 321-fold more active than other quinolones against quinolone-susceptible and quinolone-resistant Gram-positive bacteria [13] . A subsequent and more comprehensive study showed that ozenoxacin has potent antibacterial activity against staphylococci and streptococci, irrespective of their levofloxacin susceptibility status [14] .
This article presents additional surveillance study data generated during development of ozenoxacin. The antibacterial activity of ozenoxacin against Gram-positive and Gram-negative clinical isolates was compared with that of other topical and systemic antibiotics used in the treatment of skin and soft tissue infections (SSTIs). As it had yet to be decided at the time of the study whether ozenoxacin was to be developed as a systemic (oral or intravenous) and/or topical formulation, in order to ascertain its full microbiological profile, its antibacterial 
Streptococci & enterococci
Ozenoxacin was highly active against levofloxacin nonsusceptible/susceptible streptococci and Enterococcus spp. (Table 3 ) with a MIC 90 of 0.03 mg/l against combined β-haemolytic streptococci; 0.06 against combined viridans streptococci; 0.03 mg/l against S pneumoniae; and 1 mg/l against enterococci including E. faecalis. In SSTI-derived isolates (Table 4) , ozenoxacin had the lowest or equal-lowest MIC 90 compared with 22 other antibacterial agents tested against the following bacteria: combined β-haemolytic streptococci, S. agalactiae, combined viridans streptococci, S. anginosus, S. constellatus, S. oralis and S. pneumoniae. The activity of ozenoxacin against remaining streptococci and enterococci was generally within one dilution of the most active compound. Against combined β-haemolytic streptococci, ozenoxacin had the lowest MIC 90 (0.03 mg/l) of all 23 antibacterial agents tested. Meropenem, penicillin, amoxicillin-clavulanic acid, ceftriaxone, cefuroxime and retapamulin each had a MIC 90 of 0.06 mg/l, while ampicillin, teicoplanin and tigecycline each had a MIC 90 of 0.012 mg/l. MIC 90 values for all other agents were higher than that of ozenoxacin: 0.25 mg/l for moxifloxacin, daptomycin, piperacillintazobactam and trimethoprim-sulfamethoxazole; 0.5 mg/l for vancomycin; 1 mg/l for mupirocin, levofloxacin, ceftazidime and linezolid; 4 mg/l for clarithromycin; 16 mg/l for fusidic acid; and 64 mg/l for tetracycline and neomycin.
Against E. faecalis (Table 4) , tigecycline (MIC 90 of 0.12 mg/l) was the most active agent, followed by amoxicillinclavulanic acid and tetracycline (both 0.05 mg/dl), then ozenoxacin and ampicillin (both 1 mg/dl). future science group 10.2217/fmb-2019-0089 Table 5 . Summary minimum inhibitory concentration data of ozenoxacin for Gram-negative bacteria. 
Gram-negative bacteria

Enterobacteriaceae
Ozenoxacin had a MIC 90 of more than 2 mg/l for combined species of the Enterobacteriaceae family, with values ranging from 0.12 mg/l for Citrobacter koseri, 0.25 mg/l for Shigella sonnei, 0.5 mg/l for Enterobacter asburiae and S. flexneri, 1 mg/l for Klebsiella oxytoca, and more than 2 mg/l for all remaining species (Table 5) . MIC values against Gram-negative bacteria derived from SSTIs were compared for ozenoxacin and 13 other antibacterial agents. Based on MIC 90 , ozenoxacin was the most active quinolone against combined Enterobacteriaceae, E. cloacae, E. coli, K. pneumoniae and Morganella morganii. In contrast, ozenoxacin was the least active quinolone against C. freundii, C. koseri, E. aerogenes, K. oxytoca and Serratia marcescens. However, the quinolones were generally of similar activity with MIC 90 values within one or two dilutions of each other.
For combined species of Enterobacteriaceae, the most active compounds (as measured by MIC 90 ) were meropenem (0.06 mg/l), tigecycline (2 mg/l) and ozenoxacin (>2 mg/l), followed by neomycin (4 mg/l), ciprofloxacin (>4 mg/l), levofloxacin and moxifloxacin (each >8 mg/l). All other antibacterial agents had MIC 90 values of 32 to >128 mg/l (Table 6 ).
Other Gram-negative bacteria For other Gram-negative bacteria (Table 5) but was not included in the present study. The Japanese results highlight that ozenoxacin is markedly more active than gentamicin against the most common Gram-positive bacteria found in SSTIs. Another Japanese study showed that MICs of ozenoxacin against three levofloxacin-susceptible Propionibacterium acnes strains (MIC of levofloxacin; ≤4 μg/ml) and three levofloxacin-resistant P. acnes strains (MIC of levofloxacin; ≥8 μg/ml) ranged from 0.03 to 0.06 μg/ml and from 0.25 to 0.5 μg/ml, respectively [33] . These results suggest that ozenoxacin has a potent bactericidal activity against both levofloxacin-susceptible and levofloxacin-resistant P. acnes, a microorganism not included in the present study. A 2% lotion formulation of ozenoxacin has been approved since 2015 in Japan for treatment of inflamed acne.
In this study, the quinolones (ozenoxacin, ciprofloxacin, levofloxacin and moxifloxacin) exhibited comparable activity against Enterobacteriaceae, whereas ozenoxacin was the most active quinolone against E. cloacae, E. coli, K. pneumoniae and M. morganii. Ozenoxacin had lower activity than other quinolones against C. freundii, C. koseri, K. aerogenes, K. oxytoca and S. marcescens, although the differences were relatively small.
As SSTIs are caused mainly by Gram-positive cocci (especially S. aureus and S. pyogenes), the numbers of Gramnegative isolates derived exclusively from SSTIs were insufficient to compare ozenoxacin with other antibacterial agents. Moreover, other commonly used topical antibiotics such as mupirocin [34] and fusidic acid [35] have no or limited activity against Gram-negative isolates. The vast majority of Haemophilus spp. and M. catarrhalis isolates were derived from RTIs. Nevertheless, irrespective of the source, ozenoxacin was highly active against all Haemophilus spp. (0.03 mg/l), H. influenzae (0.015 mg/l) and M. catarrhalis (MIC 90 of 0.008 mg/l), and was somewhat less active against H. parainfluenzae (0.25 mg/l).
Conclusion
In conclusion, ozenoxacin was shown to be a potent antibacterial agent against Gram-positive (staphylococci and streptococci) isolates and showed activity against some Gram-negative isolates. The high activity of ozenoxacin in staphylococcal and streptococcal spp. including methicillin and quinolone-resistant strains most commonly associated with childhood impetigo suggests that ozenoxacin may be a valuable alternative to other topical antibiotics in the eradication of these same bacterial species derived from SSTIs.
Summary points
• Ozenoxacin, a novel nonfluorinated quinolone with bactericidal activity, is approved in the USA, Canada and 12 EU countries as a 1% cream formulation for treatment of impetigo and in Japan as a 2% lotion formulation for treatment of superficial skin infections and acne.
• During development of ozenoxacin, surveillance studies compared its in vitro antibacterial activity with that of other topical and systemic antibacterial agents.
• In 2010, a total of 10,054 Gram-positive and Gram-negative isolates were collected from 128 centers worldwide; isolates were derived mainly from skin and soft tissue infections (SSTIs; 44.8%) and respiratory tract infections (38.1%).
• Minimum inhibitory concentrations were determined for 23 and 13 antimicrobial agents, respectively, using standard broth microdilution methods.
• Ozenoxacin exhibited high in vitro activity against susceptible, and methicillin-or levofloxacin-resistant, Gram-positive bacteria (Staphylococcus aureus, coagulase-negative staphylococci, β-haemolytic streptococci, viridans streptococci, enterococci and Streptococcus pneumoniae isolates).
• In the case of Gram-positive SSTI isolates, ozenoxacin was generally more active than mupirocin or fusidic acid and other quinolones.
• Ozenoxacin showed one or two dilutions less activity against Enterobacteriaceae isolates, except for Escherichia coli, than other quinolones tested.
• In the case of Gram-negative SSTI isolates, no comparisons of ozenoxacin were made with mupirocin and fusidic acid as these antibiotics are not active against these bacteria.
• Ozenoxacin is a potent antimicrobial agent mainly against susceptible and resistant strains of Gram-positive isolates (staphylococci and streptococci), and shows activity against some Gram-negative isolates.
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